A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-2)

This study will assess the safety and efficacy of ixekizumab (LY2439821) compared to etanercept and placebo in participants with moderate to severe chronic plaque psoriasis.


Study Type: Interventional  (Clinical Trial)
Actual Enrollment: 1224 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of LY2439821 to Etanercept and Placebo in Patients With Moderate-to-Severe Plaque Psoriasis
Actual Study Start Date: May 18, 2012
Actual Primary Completion Date: March 25, 2014
Estimated Study Completion Date: July 10, 2019

Arm:
- Experimental: 80 mg ixekizumab Dosing Regimen 1
- Experimental: 80 mg ixekizumab Dosing Regimen 2
- Experimental: 80 mg ixekizumab Dosing Regimen 3
- Active Comparator: 50 mg etanercept
- Placebo Comparator: Placebo for ixekizumab


Related journal:
- Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis.